Here are five key details:
- Dexamethasone is an inexpensive, on-the-shelf steroid used to treat conditions such as asthma, rheumatoid arthritis and certain cancers.
- The study, called RECOVERY, randomly prescribed 2,104 COVID-19 patients 6 milligrams of dexamethasone daily, which they took intravenously or by mouth. They were compared to 4,321 patients who received only standard care.
- Dexamethasone reduced the death rate by 35 percent in patients who needed to be on a ventilator and 20 percent in patients who needed oxygen but not a ventilator.
- The study did not find dexamethasone to be statistically beneficial in patients who did not require oxygen.
- The full study has yet to be published or face scientific scrutiny.
More articles on pharmacy:
FDA rescinds hydroxychloroquine emergency use authorization
10 exec moves affecting the pharma industry
U of Illinois to test Moderna’s COVID-19 vaccine in older and minority populations
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
